GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Return-on-Tangible-Asset

Baudax Bio (Baudax Bio) Return-on-Tangible-Asset : -93.96% (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Baudax Bio's annualized Net Income for the quarter that ended in Sep. 2023 was $-7.74 Mil. Baudax Bio's average total tangible assets for the quarter that ended in Sep. 2023 was $8.23 Mil. Therefore, Baudax Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -93.96%.

The historical rank and industry rank for Baudax Bio's Return-on-Tangible-Asset or its related term are showing as below:

BXRXQ' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1442.7   Med: -269.16   Max: -55.05
Current: -83.79

During the past 6 years, Baudax Bio's highest Return-on-Tangible-Asset was -55.05%. The lowest was -1442.70%. And the median was -269.16%.

BXRXQ's Return-on-Tangible-Asset is ranked worse than
73.35% of 1546 companies
in the Biotechnology industry
Industry Median: -40.51 vs BXRXQ: -83.79

Baudax Bio Return-on-Tangible-Asset Historical Data

The historical data trend for Baudax Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Return-on-Tangible-Asset Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial -1,373.10 -202.33 -223.70 -55.05 -314.61

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -737.09 -347.58 710.36 -436.46 -93.96

Competitive Comparison of Baudax Bio's Return-on-Tangible-Asset

For the Biotechnology subindustry, Baudax Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Return-on-Tangible-Asset falls into.



Baudax Bio Return-on-Tangible-Asset Calculation

Baudax Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-58.795/( (29.472+7.905)/ 2 )
=-58.795/18.6885
=-314.61 %

Baudax Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-7.736/( (8.58+7.886)/ 2 )
=-7.736/8.233
=-93.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data.


Baudax Bio  (OTCPK:BXRXQ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Baudax Bio Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines

From GuruFocus

Baudax Bio Announces Closing of $4 Million Public Offering

By GlobeNewswire GlobeNewswire 05-01-2023

Q2 2020 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2022 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Announces Pricing of $4 Million Public Offering

By sperokesalga sperokesalga 04-27-2023

Baudax Bio Announces Closing of $4 Million Public Offering

By sperokesalga sperokesalga 05-01-2023

Baudax Bio Acquires TeraImmune, Inc.

By Marketwired 06-30-2023

Baudax Bio Announces Date of Reconvened Annual Meeting

By sperokesalga sperokesalga 06-06-2023